Jereme M. Sylvain - Mar 8, 2023 Form 4 Insider Report for DEXCOM INC (DXCM)

Role: EVP Chief Financial Officer
Signature: Jereme Sylvain
Stock symbol: DXCM
Transactions as of: Mar 8, 2023
Transactions value $: $22
Form type: 4
Date filed: 3/10/2023, 02:57 PM
Previous filing: Feb 22, 2023
Next filing: Mar 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DXCM	Common Stock	Award	$21.80	+21.8K	+33.51%	$0.00^*	86.7K	Mar 8, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
F2	Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.

Content

Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in three equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

Included in this number are 54,661 unvested restricted stock units, 21,769 of which were granted on March 8, 2023 and shall vest through March 8, 2026, 14,124 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 11,700 of which were granted on December 15, 2021 and shall vest through December 15, 2024, 7,068 of which were granted on March 8, 2021 and shall vest through March 8, 2024.